Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 6/20 | 0.40 |
| ▸ | NPC1 | O15118 | 5/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | AHR | P35869 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | COMT | P21964 | 1/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16478033 | 0.82 | PIK3CG (0.50) | KDM4EALDH1A1L3MBTL1MAPK1HTT | |
| SCHEMBL3132802 | 0.82 | KDM4E (0.39) | KDM4EALDH1A1L3MBTL1MAPK1HTT | |
| SCHEMBL8811373 | 0.82 | KDM4E (0.47) | KDM4EALDH1A1L3MBTL1MAPK1HTT | |
| SCHEMBL1523849 | 0.82 | KDM4E (0.47) | KDM4EALDH1A1L3MBTL1MAPK1HTT | |
| SCHEMBL15690263 | 0.82 | KDM4E (0.47) | KDM4EALDH1A1L3MBTL1MAPK1HTT | |
| SCHEMBL3345939 | 0.82 | KDM4E (0.47) | KDM4EALDH1A1L3MBTL1MAPK1HTT | |
| SCHEMBL21097673 | 0.80 | KDM4E (0.36) | KDM4EALDH1A1L3MBTL1MAPK1HTT | |
| SCHEMBL20048908 | 0.80 | CSNK1A1 (0.45) | KDM4EALDH1A1L3MBTL1MAPK1HTT | |
| SCHEMBL25124610 | 0.79 | ALDH1A1 (0.44) | KDM4EALDH1A1L3MBTL1MAPK1HTT | |
| SCHEMBL17132540 | 0.79 | KDM4E (0.44) | KDM4EALDH1A1L3MBTL1MAPK1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4185293-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING PYRUVATE KINASE | The Regents of The University of Michigan (US) | 2023-05-31 | — | — | EP | disclosed |
| US-20220402915-A1 | BCL-2 INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2022-12-22 | — | — | US | disclosed |
| WO-2022020424-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING PYRUVATE KINASE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-01-27 | — | — | WO | disclosed |
| WO-2019118571-A1 | ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. (US) | 2019-06-20 | — | — | WO | disclosed |
| US-10000487-B2 | Heterocyclic compounds that inhibit the kinase activity of Mnk useful for treating various cancers | EFFECTOR THERAPEUTICS, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| WO-2018067704-A1 | ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. (US) | 2018-04-12 | — | — | WO | disclosed |
| US-9546153-B2 | Bicyclic heterocycle substituted pyridyl compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-01-17 | — | — | US | disclosed |
| EP-2922840-B1 | BICYCLIC HETEROCYCLE SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2016-12-21 | — | — | EP | disclosed |
| US-20150274696-A1 | BICYCLIC HETEROCYCLE SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-10-01 | — | — | US | disclosed |
| US-8877707-B2 | Inhibitors of HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-8865756-B2 | Inhibitors of HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2014-10-21 | — | — | US | disclosed |
| WO-2014074657-A1 | BICYCLIC HETEROCYCLE SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-15 | — | — | WO | disclosed |
| US-20130203656-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130203656-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130096101-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130096101-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20120115855-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-8110580-B2 | Thiophene pyrazolopyrimidine compounds | ELI LILLY AND COMPANY (US) | 2012-02-07 | — | — | US | disclosed |
| WO-2010065668-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
| US-20100022560-A1 | THIOPHENE PYRAZOLOPYRIMIDINE COMPOUNDS | CHEN ZHAOGEN | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402915-A1 | BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L2 | KDM4E 3263/4885ALDH1A1 3125/4885L3MBTL1 1882/4885 |
| US-20150274696-A1 | BICYCLIC HETEROCYCLE SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE MODULATORS | IRAK4, IRAK1, IRAK3 | KDM4E 225/4885ALDH1A1 3540/4885L3MBTL1 1756/4885 |
| US-20130096101-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | KDM4E 4063/4885ALDH1A1 3636/4885L3MBTL1 3448/4885 |
| US-20100022560-A1 | THIOPHENE PYRAZOLOPYRIMIDINE COMPOUNDS | CRH, CRHR1, CRHR2 | KDM4E 4111/4885ALDH1A1 2135/4885L3MBTL1 4751/4885 |
| US-20130203656-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | KDM4E 4113/4885ALDH1A1 3492/4885L3MBTL1 3523/4885 |
| US-10000487-B2 | Heterocyclic compounds that inhibit the kinase activity of Mnk useful for treating various cancers | MAP3K9, MAP3K19, MAP3K20 | KDM4E 1316/4885ALDH1A1 4542/4885L3MBTL1 3123/4885 |
| US-20120115855-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | KDM4E 4113/4885ALDH1A1 3492/4885L3MBTL1 3523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.